Asia Pacific Automated Breast Ultrasound Systems Market size crossed USD 600 million in 2021 and is anticipated to observe around 15% growth rate between 2022 and 2028.
The incidence of breast cancer is increasing at a worrying rate across the region. Factors, such as environmental conditions, obesity, hormonal changes, and excessive alcohol consumption can escalate the risk of breast cancer. Mammography systems have restricted capabilities with respect to detecting tumor in dense breast tissues, thereby persuading ABUS manufacturers to expand their product portfolio.
Get more details on this report - Request Free Sample PDF
Asian women are 75-80% likely to be dense breasted. According to the National Center for Biotechnology Information (NCBI), Chinese women have denser breast tissues as compared to other ethnicities. ABUS technology makes it a lot easier to detect tumors in dense breasts as it creates 3D images, giving physicians better clarity on the severity of the condition. China had recorded over 20% to 30% rise in breast cancer over past decade, while high incidence of the disease was also witnessed in New Zealand and Australia.
Impact of COVID-19 on demand for ABUS in APAC
The COVID-19 pandemic had a negative influence on the Asia Pacific automated breast ultrasound systems market growth. The travel and movement restrictions imposed by regional governments made it very difficult for breast cancer patients to get their regular check-ups done. This caused a steep decline in the sales of ABUS and ABVS machines. However, the post-pandemic period looks promising as the region’s healthcare industry is gradually recovering, thereby fueling the utilization of ABUS/ABVS technologies. Efforts from healthcare organizations to encourage women towards early diagnosis of diseases after infection could bolster the industry landscape.
Asia Pacific Automated Breast Ultrasound Systems Market, By Product
The ABUS segment will register significant CAGR through 2028. Automated Breast Ultrasound Systems (ABUS) are considered one of the most effective breast cancer detection technologies as they can create high-resolution 3D images with greater accuracy. This will give doctors a better understanding of their patient’s condition. They have also successfully overcome the limitations associated with mammography systems, such as detecting cancer in dense breast tissues.
Asia Pacific Market, By Country
China automated breast ultrasound systems market will reach USD 440 million revenue by 2028, due to the consistent growth in the prevalence of breast cancer across the country. A large share of women with dense breast tissues will opt for ABUS solutions as they can effectively detect cancer in such tissues. The Government of China has also initiated several programs to promote ultrasound screening for breast cancer detection. These efforts will generate a robust demand for ABUS across the country’s hospitals and diagnostic centers.
Competitive Industry Landscape
Major players involved in the Asia Pacific automated breast ultrasound systems (ABUS) market include Canon Medical Systems, GE Healthcare, Theraclion, Hitachi Ltd., Philips, Siemens AG, and SonoCine Inc.
Strategic partnerships across the global industry will create new prospects for these companies. Advantages of modern technologies such as AI will encourage manufacturers to integrate them within their diagnostic products. Collaborations between ABUS providers will help them develop products that offer fast and more accurate automated ultrasound examinations.